(10.2: 10.4) (8.0: 14.5) Median were established using TCGA Affymetrix (1A) and Illumina (1B) datasets, n = 500 and n = 149, respectively. p-values are given between all GB samples and to the "normal" subgroup.
B SUPPLEMENTARY MATERIALS AND METHODS

TCGA databanks and related statistical analyses
We used The Cancer Genome Atlas (TCGA) datasets to analyze integrins gene expression in newly diagnosed primary GB patients [39, 49] . For gene expression, two datasets (processed data : version 2015-02-24, downloaded from https://genome-cancer.ucsc.edu) were used based either on microarray data (Affymetrix HT Human Genome U133a microarray platform by the Broad Institute of MIT and Harvard University, n = 500) or RNA-seq data (Illumina HiSeq 2000 RNA Sequencing platform by the University of North Carolina TCGA genome characterization center, n = 149). We also assessed OS using the TCGA Affymetrix dataset among a subgroup of newly diagnosed primary GB patients treated by standard chemo-radiotherapy (n = 184). For this OS analyses, gene expression levels were dichotomized based on a high expression cutoff (within the 75% quartile).
Multiple comparisons between groups were performed using Mann-Whitney U test. The BenjaminiHochberg procedure was applied for multiple comparisons (Figure 4 ; Supplementary Figures 1 and 2 ). All survival rates were estimated by the Kaplan-Meier method with 95% confidence intervals (CI). Univariate analyses were performed using Cox proportional hazard model. Multivariate analyses were then performed using Cox proportional hazard model, including prognostic clinical covariates with a p-value < 0.10 in univariate analysis (Age, G-CIMP status and Karnofsky score). All reported p-values were two-sided. For all statistical tests, differences were considered significant at the 5% level. Statistical analysis was performed using STATA 12 software.
